Alexis Tabah

Dr. Alexis Tabah

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2020 in Intensive Care Medicine
Verified
Journal Article
Closed access
PDF file
jean-francois timsitjean-francois timsit
jean-francois timsit
EREtienne Ruppé
Etienne Ruppé
FBFrançois Barbier
François Barbier
ATAlexis Tabah
Alexis Tabah
MBMatteo Bassetti
Matteo Bassetti

26 September 2012 in Intensive Care Medicine
Verified
Journal Article
Closed access
PDF file
ATAlexis Tabah
Alexis Tabah
Despoina KoulentiDespoina Koulenti
Despoina Koulenti
FEFelicity Edwards
Felicity Edwards
BMBenoît Misset
Benoît Misset
JVJordi Valles
Jordi Valles
JTJean-François Timsit
Jean-François Timsit

27 January 2010 in JAMA
Verified
Journal Article
Open access
PDF file
CICOIITSS Study Investigators
COIITSS Study Investigators
DAdjillali Annane
djillali Annane
ACAlain Cariou
Alain Cariou
VMVirginie Maxime
Virginie Maxime
EAElie Azoulay
Elie Azoulay
SCSylvie Chevret
Sylvie Chevret
Research from JAMA — Corticosteroid Treatment and Intensive Insulin Therapy for Septic Shock in Adults — A Randomized Controlled Trial

10 February 2023 in Intensive Care Medicine
Verified
Journal Article
Closed access
PDF file
ATAlexis Tabah
Alexis Tabah
NBNiccolò Buetti
Niccolò Buetti
QSQuentin Staiquly
Quentin Staiquly
SRStéphane Ruckly
Stéphane Ruckly
MAMurat Akova
Murat Akova
JTJean-François Timsit
Jean-François Timsit

15 September 2009 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
NSNina Singh
Nina Singh
JAJose M. Aguado
Jose M. Aguado
HBHugo Bonatti
Hugo Bonatti
GFGraeme Forrest
Graeme Forrest
KGKrishan L. Gupta
Krishan L. Gupta
OLOlivier Lortholary
Olivier Lortholary
BackgroundClinical characteristics, risks, and outcomes in solid organ transplant (SOT) recipients with zygomycosis in the era of modern immunosuppre

23 December 2015 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
PDF file
ATAlexis Tabah
Alexis Tabah
MCMenino Cotta
Menino Cotta
JMJOSE GARNACHO MONTERO
JOSE GARNACHO MONTERO
JSJeroen Schouten
Jeroen Schouten
JRJason Roberts
Jason Roberts
JWJan J. De Waele
Jan J. De Waele
Antimicrobial de-escalation (ADE) is a strategy to reduce the spectrum of antimicrobials and aims to prevent the emergence of bacterial resistance. We present a systematic review describing the definitions, determinants and outcomes associated with ADE. We included 2 randomized controlled trials and 12 cohort studies. There was considerable variability in the definition of ADE. It was more frequently performed in patients with broad-spectrum and/or appropriate antimicrobial therapy (P = .05 to .002), when more agents were used (P = .002), and in the absence of multidrug-resistant pathogens (P < .05). Where investigated, lower or improving severity scores were consistently associated with ADE (P = .04 to <.001). The pooled effect of ADE on mortality is protective (relative risk, 0.68; 95% confidence interval, .52–.88). Because the determinants of ADE are markers of clinical improvement and/or of lower risk of treatment failure this effect on mortality cannot be retained as evidence. None of the studies were designed to investigate the effect of ADE on antimicrobial resistance.